Antonella D'Arminio Monforte

No ORCID on file · 1 paper in corpus
2022
Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)
SSRN Electronic Journal ·doi:10.2139/ssrn.4289473

Background: Among interleukin-6 inhibitors suggested for use in COVID-19, there are few robust evidences for the efficacy of sarilumab. Herein, we evaluated the efficacy and safety of sarilumab in severe COVID-19.Methods: In this phase 3, o…